Ignite Creation Date:
2024-05-05 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00441337
Status:
COMPLETED
Last Update Posted:
2015-02-20
First Post:
2007-02-27
Brief Title:
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase 1 Open Label Dose-escalation Safety and Pharmacokinetic Study of MDX-1106 in Patients With Selected or Relapsed Malignancies
Status:
COMPLETED
Status Verified Date:
2015-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MDX1106-01
Brief Summary:
To evaluate the safety tolerability efficacy and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer colorectal cancer malignant melanoma clear cell renal cell cancer or hormone refractory prostate cancer
Detailed Description:
Six patients enrolled at each dose level of 03 10 30 and 10mgkg the remaining 10 to 15 patients may subsequently be enrolled at a dose at or below the maximum tolerated dose MTD during the dose-escalation portion of the study Patients who respond may receive additional doses of drug
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MDX1106-01 | OTHER | BMS | None |